Since telitacicept targets both BLyS/BAFF and APRIL, it has potential use in the treatment of many autoimmune illnesses linked to B cells such as IgAN, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) [25, 50]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.